Summary

Familial combined hyperlipidemia is a highly atherogenic disorder that affects 1% to 2% of the Western world [Shoulders CC et al. Hum Mol Genet 2004]. It occurs in approximately 20% of patients who develop coronary heart disease before age 60 [Aouizerat BE et al. Am J Hum Genet 1999]. This article discusses the need for continued research of treatments for familial hypercholesterolemia (FH). Emerging therapies include apolipoprotein B (ApoB) inhibitors, microsomal triglyceride transfer protein (MTP) inhibitors, and proprotein convertase subtilism kexin 9 (PCSK9) inhibitors [Alonso R et al. Expert Rev Cardiovasc Ther 2013].